临床试验结果表明，血清素能致幻剂可有效治疗目前批准的药物疗法不足的精神疾病。然而，开发迷幻药物面临着独特的挑战，例如缓解与迷幻体验相关的高度焦虑。我们构思了一种新策略，可以通过定义的电磁信号（ES）来潜在地减轻迷幻效果。我们记录了血清素 2 受体 (5-HT2R) 激动剂 (±)-2,5-二甲氧基-4-碘苯丙胺 (DOI) 发出的电磁场，并将其转换为可播放的 WAV 文件。然后，我们将 DOI WAV ES 暴露给小鼠，以评估其对 DOI 引发的 5-HT2AR 依赖性头部抽搐反应 (HTR) 的影响。 DOI WAV 信号显着减弱了 0.1 和 0.3mg/kg 皮下 DOI 引起的小鼠的 HTR（分别为 p<<0.05 和 p<0.01）。加扰的 WAV 信号不会影响 DOI 引发的 HTR，表明 DOI WAV 信号的特异性。这些结果证明特定的 ES 可以调节 5-羟色胺能致幻剂的精神作用。我们在先前的研究中讨论了 DOI WAV 信号的独特效应的假定解释，这些研究证明了 ES 对治疗其他疾病（包括疼痛和癌症）的功效。

Results from clinical trials show that serotonergic psychedelics have efficacy in treating psychiatric disorders, where currently approved pharmacotherapies are inadequate. Developing psychedelic medicines, however, comes with unique challenges, such as tempering heightened anxiety associated with the psychedelic experience. We conceived a new strategy to potentially mitigate psychedelic effects with defined electromagnetic signals (ES). We recorded the electromagnetic fields emitted by the serotonin 2 receptor (5-HT2R) agonist (±)-2,5-dimethoxy-4-iodoamphetamine (DOI) and converted them to a playable WAV file. We then exposed the DOI WAV ES to mice to assess its effects on the DOI-elicited, 5-HT2AR dependent head-twitch response (HTR). The DOI WAV signal significantly attenuated the HTR in mice elicited by 0.1 and 0.3 mg/kg subcutaneous DOI (p < 0.05 and p < 0.01, respectively). A scrambled WAV signal did not affect the DOI-elicited HTR, suggesting specificity of the DOI WAV signal. These results provide evidence that defined ES could modulate the psychoactive effects of serotonergic psychedelics. We discuss putative explanations for the distinct effects of the DOI WAV signal in the context of previous studies that demonstrate ES's efficacy for treating other conditions, including pain and cancer.